BioLineRx Ltd. Sponsored ADR Quality Score
BLRX
Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Negative FCF, no valuation support
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Shrinking >2%, active buybacks
Net cash position, no leverage concern
Below 8%, may not cover cost of capital
BioLineRx Ltd. Sponsored ADR (BLRX) quality: score, margins and returns
BioLineRx Ltd. Sponsored ADR (BLRX) scores 20/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100, on -874.3% operating margins and -26.2% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.
Frequently asked
Is BioLineRx Ltd. Sponsored ADR (BLRX) a high-quality business?+
BioLineRx Ltd. Sponsored ADR scores 20 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -874.3% operating margin and a -26.2% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does BioLineRx Ltd. Sponsored ADR's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from BLRX's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where BioLineRx Ltd. Sponsored ADR scores well and where it falls behind.
What is BioLineRx Ltd. Sponsored ADR's return on invested capital (ROIC)?+
BioLineRx Ltd. Sponsored ADR earns about -26.2% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to BLRX's margins and growth on this scorecard to judge durability.
How profitable is BioLineRx Ltd. Sponsored ADR?+
BioLineRx Ltd. Sponsored ADR runs an operating margin of about -874.3% and a net margin of about -728.4%. Revenue has grown at roughly -50.4% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.
Peers
Biotechnology · Pick stocks to compare with BLRX
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BLRX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.